Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Efavirenz in an obese HIV-infected patient - a report and an in vitro-in vivo extrapolation model indicate risk of underdosing
Journal
Antiviral Therapy
Volume
17
Number
7
Pages
1381-4
Mesh terms
Benzoxazines, pharmacokinetics; Body Mass Index; Computer Simulation; Drug Dosage Calculations; Drug Monitoring, methods; HIV, pathogenicity; HIV Infections, virology; Humans; Male; Middle Aged; Obesity, pathology; RNA, Viral, blood; Reverse Transcriptase Inhibitors, pharmacokinetics; Risk Factors; Viral Load
Abstract
Here, we report suboptimal efavirenz exposure in an obese patient treated with the standard 600 mg dose. Tripling the dose allowed attainment of therapeutic efavirenz concentrations. We developed an in vitro-in vivo extrapolation model to quantify dose requirements in obese individuals. Obesity represents a risk factor for antiretroviral therapy underdosing.
